Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Videos

Showing 47 results.

MM - 1078 Video-1

OPTec/OPTal: A Phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Thomas S. Lin

MM - 1100 Video-1

Impact of Dose Modifications on Efficacy Outcomes With Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: Insights From the DREAMM-7 Third-Line or Later Proteasome Inhibitor/Immunomodulatory Agent-Exposed Subgroup

Al-Ola Abdallah

MM - 1135 Video-1

Efficacy Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Baseline Renal Impairment Treated With at Least 2 Prior Lines of Therapy in the DREAMM-7 Trial

Robert Rifkin

MM - 1168 Video-1

Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial

Robert Rifkin

MM - 326 Video-1

New IMS/IMWG Consensus Genomic Staging (CGS) Risk Criteria by Next-Generation Sequencing (NGS): Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study

Meletios A Dimopoulos

MM - 338 Video-1

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

Saad Z Usmani

MM - 349 Video-1

Teclistamab Plus Daratumumab (Tec-Dara) in Patients With Relapsed Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk

Kaci Ernst

MM - 467 Video-1

Identification of RNASEL and ROCK1 as Geometric Bottlenecks in Multiple Myeloma via Discrete Ricci Curvature Analysis

Alamin Mustafa

MM - 826 Video-1

National Trends in Pneumonia-Related Admissions Among Patients With Multiple Myeloma

Jackson Brunner

MPN - 481 Video-1

Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, is Well Tolerated and Achieves Rapid and Sustained Hematologic and Molecular Responses in Patients With Essential Thrombocythemia (ET)

Haris Ali

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.